Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors to Stabilize Coronary Atherosclerosis After Acute Myocardial Infarction in Patients With Diabetes Mellitus
2025-523375-29-00Phase 3Authorised
- Sponsor
- Humanitas Research Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin, dapagliflozin and canagliflozin in type 2 diabetes mellitus (T2DM), myocardial infarction (MI) and coronary arteriosclerosis, sponsored by Humanitas Research Hospital. Primary endpoint: Change in total coronary percentage atheroma volume on native segments at 12 months. Planned start Feb 2026; status: authorised.
02
Drugs
empagliflozindapagliflozincanagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)myocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on 2025-523375-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523375-29-00.